Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
C SessaL Gianni

Abstract

The combination of trabectedin (T) and doxorubicin (D) was brought into clinical development in soft tissue sarcoma (STS) and advanced breast cancer (ABC) because of its in vitro and in vivo additive anti-tumour effect, the fact that there are no overlapping toxicities and the anti-tumour activity of T in those tumours. Feasibility and anti-tumour activity of T+D administered every 3 weeks were evaluated in 38 patients (STS=29, ABC=9) untreated for advanced disease. D was given at 60 mg/m(2) and T at escalating doses from 600 to 800 microg/m(2), which was the maximum tolerated dose due to dose-limiting febrile neutropenia and asthenia. The recommended dose--given to 18 patients in total--was 700 microg/m(2) T with 60 mg/m(2) D. The pharmacokinetic profile of T and D at cycle 1 was analysed in 20 patients. The most common toxicities included a severe but reversible ASAT/ALAT increase (94%), nausea/vomiting, neutropenia, asthenia/fatigue, stomatitis. Partial response and stable disease were assessed in 18% and 56% of STS patients and in 55% and 33% of ABC patients. No pharmacokinetic interaction between T and D was observed. The lack of cumulative toxicity and related complications and the promising activity in STS support furthe...Continue Reading

References

Jul 1, 1997·Current Opinion in Oncology·L Y DirixA T Van Oosterom
Jun 7, 2000·Proceedings of the National Academy of Sciences of the United States of America·S JinK W Scotto
Jun 5, 2003·Cancer Chemotherapy and Pharmacology·Daniela MecoRiccardo Riccardi
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cristiana SessaNicoletta Colombo
Jun 26, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Giovanna Damia, Maurizio D'Incalci
Jul 28, 2007·Proceedings of the National Academy of Sciences of the United States of America·Daniele Grazziotin SoaresAnnette K Larsen
Feb 5, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M TavecchioG Damia
Apr 2, 2008·Cancer Chemotherapy and Pharmacology·Wells A MessersmithManuel Hidalgo
May 24, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M von MehrenR B Cohen
Oct 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean-Yves BlayAxel Le Cesne

❮ Previous
Next ❯

Citations

Sep 1, 2005·Investigational New Drugs·J H BeumerJ H M Schellens
Apr 5, 2011·Antioxidants & Redox Signaling·Laura A A Gilliam, Daret K St Clair
May 22, 2010·Current Opinion in Oncology·Paolo G CasaliMaurizio D'Incalci
Feb 20, 2010·Drugs·Natalie J Carter, Susan J Keam
Nov 1, 2011·Drugs·Sujana Movva, Claire Verschraegen
Apr 3, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S DelalogeJ Lubinski
Sep 12, 2014·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Christian LeporiniEmilio Russo
Apr 24, 2014·Current Oncology Reports·Jay Patrick LopezAnthony Elias
Aug 13, 2009·Expert Review of Anticancer Therapy·Thomas Schmitt, Bernd Kasper
Jun 18, 2010·Expert Review of Anticancer Therapy·Josep M Del CampoAna Oaknin
Feb 17, 2015·Marine Drugs·Bradley J PetekRobin L Jones
Jun 6, 2009·Expert Review of Anticancer Therapy·Laurence BoudouPhilippe A Cassier
Nov 26, 2015·Expert Opinion on Investigational Drugs·Maurizio D'Incalci, Alberto Zambelli
Sep 12, 2009·Expert Opinion on Pharmacotherapy·Kristen N Ganjoo, S R Patel
Dec 21, 2010·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Aviad HoffmanDina Lev
Jul 20, 2010·Annales pharmaceutiques françaises·C Monneret
May 8, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C SessaL Gianni
Mar 22, 2015·The Lancet Oncology·Jonathan NoujaimRobin L Jones
Jun 20, 2015·Sarcoma·Frédéric AmantPatricia Pautier
Apr 5, 2016·Expert Review of Anticancer Therapy·Maristella SaponaraAlessandro Gronchi
May 29, 2016·Advances in Therapy·Erlinda M GordonSant P Chawla
Sep 13, 2016·Expert Opinion on Pharmacotherapy·Ritika Zijoo, Margaret von Mehren
Apr 28, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M A RudekS D Baker
Feb 14, 2006·Seminars in Oncology·Raymond NgMichael D Green
Jan 11, 2017·British Journal of Cancer·Michela RomanoMaurizio D'Incalci
Dec 19, 2017·Frontiers in Oncology·Yevette McGovernRobin L Jones
Aug 18, 2009·The Oncologist·Meredith K ChukElizabeth Fox
May 24, 2017·Current Treatment Options in Oncology·Ravin Ratan, Shreyaskumar R Patel
Mar 11, 2010·Cancer Research·Giovanni GermanoPaola Allavena

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
C SessaL Gianni
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Jean-Yves BlayAxel Le Cesne
© 2021 Meta ULC. All rights reserved